Withanolide

Withanolides are a class of over 300 naturally occurring steroidal lactones derived primarily from Withania somnifera (ashwagandha), biosynthesized via the mevalonate pathway. Their primary bioactive mechanisms involve modulation of NF-κB signaling, Hsp90 inhibition, and binding to steroid hormone receptors, driving their adaptogenic and anti-inflammatory properties.

Origin & History

Withanolides are a group of over 300 naturally occurring steroidal lactones built on an ergostane skeleton, primarily extracted from Withania somnifera (ashwagandha) roots and leaves. They are isolated through alcoholic extraction methods, with concentrations ranging from 0.001 to 0.5% of dry weight in plant material.

Historical & Cultural Context

The research confirms Withania somnifera is described as 'a medicinal plant of immense repute' and 'a multipurpose medicinal plant,' but provides no specific details about traditional applications, duration of historical use, or cultural contexts.

Health Benefits

• The research provided focuses on phytochemical characterization rather than clinical outcomes - no specific health benefits with evidence quality can be cited from these sources
• Biosynthetic pathway studies show withanolides are produced via the mevalonate pathway
• Over 300 distinct variants have been identified including withanolide A, D, withaferin A, and withanone
• Gene expression studies demonstrate HMGR-1 upregulation correlates with withanolide accumulation
• No clinical trials or health outcome data are present in the provided research

How It Works

Withanolide A and withaferin A bind to the C-terminal domain of Hsp90, disrupting client protein stabilization and promoting proteasomal degradation of oncoproteins such as Akt and CDK4. Withaferin A also covalently binds to the IKKβ subunit of the IκB kinase complex, suppressing NF-κB nuclear translocation and downstream pro-inflammatory cytokine expression including TNF-α and IL-6. Additionally, withanolides interact with glucocorticoid receptors and modulate hypothalamic-pituitary-adrenal axis activity, contributing to observed reductions in serum cortisol in human trials.

Scientific Research

The provided research dossier contains no clinical trials, randomized controlled trials, or meta-analyses evaluating withanolide efficacy for health conditions. The available sources focus exclusively on phytochemical characterization, biosynthetic pathways, and structural identification rather than clinical outcomes or PMIDs.

Clinical Summary

Human clinical trials have focused predominantly on full-spectrum ashwagandha root extracts standardized to withanolide content (typically 2.5–5%) rather than isolated withanolide compounds, limiting direct attribution of effects. A 60-participant RCT (Chandrasekhar et al., 2012) using 300 mg twice-daily extract standardized to withanolides reported a 27.9% reduction in serum cortisol and significant improvements on the Perceived Stress Scale versus placebo. A separate 8-week RCT (n=57) demonstrated statistically significant improvements in testosterone levels and muscle recovery with withanolide-standardized extract versus placebo. Evidence quality for isolated withanolides in humans remains low, with most mechanistic data derived from in vitro and rodent models; large-scale phase II/III trials on purified withanolides are absent.

Nutritional Profile

Withanolide is a bioactive steroidal lactone compound (C28 ergostane-type skeleton), not a conventional nutritional ingredient with macronutrients or micronutrients. Bioactive compound data: Steroidal lactone core structure with molecular formula typically C28H38O6 (withanolide A) to C28H32O6 (withaferin A) depending on variant; molecular weights ranging approximately 470–500 g/mol across 300+ identified variants. Key variants include Withanolide A (primary immunomodulatory form), Withanolide D, Withaferin A (most studied, potent bioactive), and Withanone. Concentrations in Withania somnifera root extract: Withanolides total 0.001–0.05% in raw root dry weight; standardized commercial extracts typically concentrated to 2.5–35% total withanolides. Withaferin A typically 0.0012–0.002% in raw root; Withanolide A approximately 0.001–0.003% dry weight. Biosynthetic origin: mevalonate pathway (terpenoid biosynthesis), classifying these as triterpenoid-derived steroidal lactones. Bioavailability notes: Oral bioavailability is moderate; lipophilic nature facilitates intestinal absorption but first-pass hepatic metabolism is significant. Co-administration with piperine or lipid-based delivery systems reported to enhance absorption. Half-life data limited in humans. No caloric, protein, fat, or carbohydrate contribution as an isolated compound. Micronutrient content: negligible as an isolated phytochemical.

Preparation & Dosage

No clinically studied dosage ranges are available in the provided research. The sources indicate total withanolide content in plant material ranges from 0.001-0.5% of dry weight, but do not specify standardized extract doses or clinical dosing protocols. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient data in provided research to determine synergistic ingredients

Safety & Interactions

Ashwagandha extracts standardized to withanolides are generally well-tolerated at doses of 300–600 mg daily, with the most commonly reported adverse effects being mild gastrointestinal upset, loose stools, and drowsiness. Withanolides may potentiate the effects of sedative medications (benzodiazepines, barbiturates) and thyroid hormone therapy, as preclinical and limited clinical data suggest thyroid-stimulating activity including elevated T3 and T4 levels. Withaferin A exhibits potent cytotoxic activity in vitro and animal models, raising theoretical concerns about concurrent use with immunosuppressants or chemotherapy agents, though no confirmed clinical interactions have been established. Withanolide-containing supplements are contraindicated in pregnancy due to historical use as an abortifacient and evidence of uterotonic effects in animal studies, and safety during lactation has not been established.